Visit https://www.peervoice.com/UHN860 to view the entire programme with slides. After completing “Seeking a More Positive Outlook in Patients With mTNBC? Treatment Advances and How to Apply Them”, participants will be able to: Describe the efficacy and safety data for recent treatment options for metastatic triple-negative breast cancer (mTNBC); Evaluate the clinical implications of the evidence for new treatments on real-life practices; Identify which patients are most likely to benefit from the new treatment options, such as the TROP2-directed antibody drug-conjugate (ADC) therapies.